Abstract
Summary
Interstitial Lung Disease (ILD), also referred to as pulmonary fibrosis or interstitial pneumonia, comprises a group of conditions characterized by varying degrees of inflammation and scarring around the tiny air sacs (alveoli) in the lungs. Interstitial Lung Disease treatment market in this report.
The global market for Interstitial Lung Disease (ILD) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Interstitial Lung Disease (ILD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Interstitial Lung Disease (ILD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Interstitial Lung Disease (ILD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Interstitial Lung Disease (ILD) include Boehringer Ingelheim, Bellerophon Therapeutics, Inc, Bayer, Fujirebio (Miraca), Philips, Merck and Siemens Healthineers, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Interstitial Lung Disease (ILD), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Interstitial Lung Disease (ILD) by region & country, by Type, and by Application.
The Interstitial Lung Disease (ILD) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Interstitial Lung Disease (ILD).
Market Segmentation
By Company
Boehringer Ingelheim
Bellerophon Therapeutics, Inc
Bayer
Fujirebio (Miraca)
Philips
Merck
Siemens Healthineers
Segment by Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia
Acute Interstitial Pneumonitis
Desquamative Interstitial Pneumonitis
Others
Segment by Application
Adults
Children
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Interstitial Lung Disease (ILD) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Interstitial Lung Disease (ILD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Interstitial Lung Disease (ILD) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Interstitial Lung Disease (ILD) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Interstitial Lung Disease (ILD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Interstitial Lung Disease (ILD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Interstitial Lung Disease (ILD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Interstitial Lung Disease (ILD) include Boehringer Ingelheim, Bellerophon Therapeutics, Inc, Bayer, Fujirebio (Miraca), Philips, Merck and Siemens Healthineers, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Interstitial Lung Disease (ILD), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Interstitial Lung Disease (ILD) by region & country, by Type, and by Application.
The Interstitial Lung Disease (ILD) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Interstitial Lung Disease (ILD).
Market Segmentation
By Company
Boehringer Ingelheim
Bellerophon Therapeutics, Inc
Bayer
Fujirebio (Miraca)
Philips
Merck
Siemens Healthineers
Segment by Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia
Acute Interstitial Pneumonitis
Desquamative Interstitial Pneumonitis
Others
Segment by Application
Adults
Children
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Interstitial Lung Disease (ILD) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Interstitial Lung Disease (ILD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Interstitial Lung Disease (ILD) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Interstitial Lung Disease (ILD) Product Introduction
1.2 Global Interstitial Lung Disease (ILD) Market Size Forecast
1.3 Interstitial Lung Disease (ILD) Market Trends & Drivers
1.3.1 Interstitial Lung Disease (ILD) Industry Trends
1.3.2 Interstitial Lung Disease (ILD) Market Drivers & Opportunity
1.3.3 Interstitial Lung Disease (ILD) Market Challenges
1.3.4 Interstitial Lung Disease (ILD) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Interstitial Lung Disease (ILD) Players Revenue Ranking (2023)
2.2 Global Interstitial Lung Disease (ILD) Revenue by Company (2019-2024)
2.3 Key Companies Interstitial Lung Disease (ILD) Manufacturing Base Distribution and Headquarters
2.4 Key Companies Interstitial Lung Disease (ILD) Product Offered
2.5 Key Companies Time to Begin Mass Production of Interstitial Lung Disease (ILD)
2.6 Interstitial Lung Disease (ILD) Market Competitive Analysis
2.6.1 Interstitial Lung Disease (ILD) Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Interstitial Lung Disease (ILD) Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Interstitial Lung Disease (ILD) as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Interstitial Pneumonia
3.1.2 Idiopathic Pulmonary Fibrosis
3.1.3 Nonspecific Interstitial Pneumonitis
3.1.4 Hypersensitivity Pneumonitis
3.1.5 Cryptogenic Organizing Pneumonia
3.1.6 Acute Interstitial Pneumonitis
3.1.7 Desquamative Interstitial Pneumonitis
3.1.8 Others
3.2 Global Interstitial Lung Disease (ILD) Sales Value by Type
3.2.1 Global Interstitial Lung Disease (ILD) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Interstitial Lung Disease (ILD) Sales Value, by Type (2019-2030)
3.2.3 Global Interstitial Lung Disease (ILD) Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Adults
4.1.2 Children
4.2 Global Interstitial Lung Disease (ILD) Sales Value by Application
4.2.1 Global Interstitial Lung Disease (ILD) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Interstitial Lung Disease (ILD) Sales Value, by Application (2019-2030)
4.2.3 Global Interstitial Lung Disease (ILD) Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Interstitial Lung Disease (ILD) Sales Value by Region
5.1.1 Global Interstitial Lung Disease (ILD) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Interstitial Lung Disease (ILD) Sales Value by Region (2019-2024)
5.1.3 Global Interstitial Lung Disease (ILD) Sales Value by Region (2025-2030)
5.1.4 Global Interstitial Lung Disease (ILD) Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.2.2 North America Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.3.2 Europe Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.4.2 Asia Pacific Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.5.2 South America Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.6.2 Middle East & Africa Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Interstitial Lung Disease (ILD) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Interstitial Lung Disease (ILD) Sales Value
6.3 United States
6.3.1 United States Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.3.2 United States Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.4.2 Europe Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.5.2 China Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.6.2 Japan Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.7.2 South Korea Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.8.2 Southeast Asia Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.9.2 India Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Boehringer Ingelheim
7.1.1 Boehringer Ingelheim Profile
7.1.2 Boehringer Ingelheim Main Business
7.1.3 Boehringer Ingelheim Interstitial Lung Disease (ILD) Products, Services and Solutions
7.1.4 Boehringer Ingelheim Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.1.5 Boehringer Ingelheim Recent Developments
7.2 Bellerophon Therapeutics, Inc
7.2.1 Bellerophon Therapeutics, Inc Profile
7.2.2 Bellerophon Therapeutics, Inc Main Business
7.2.3 Bellerophon Therapeutics, Inc Interstitial Lung Disease (ILD) Products, Services and Solutions
7.2.4 Bellerophon Therapeutics, Inc Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.2.5 Bellerophon Therapeutics, Inc Recent Developments
7.3 Bayer
7.3.1 Bayer Profile
7.3.2 Bayer Main Business
7.3.3 Bayer Interstitial Lung Disease (ILD) Products, Services and Solutions
7.3.4 Bayer Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.3.5 Fujirebio (Miraca) Recent Developments
7.4 Fujirebio (Miraca)
7.4.1 Fujirebio (Miraca) Profile
7.4.2 Fujirebio (Miraca) Main Business
7.4.3 Fujirebio (Miraca) Interstitial Lung Disease (ILD) Products, Services and Solutions
7.4.4 Fujirebio (Miraca) Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.4.5 Fujirebio (Miraca) Recent Developments
7.5 Philips
7.5.1 Philips Profile
7.5.2 Philips Main Business
7.5.3 Philips Interstitial Lung Disease (ILD) Products, Services and Solutions
7.5.4 Philips Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.5.5 Philips Recent Developments
7.6 Merck
7.6.1 Merck Profile
7.6.2 Merck Main Business
7.6.3 Merck Interstitial Lung Disease (ILD) Products, Services and Solutions
7.6.4 Merck Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.6.5 Merck Recent Developments
7.7 Siemens Healthineers
7.7.1 Siemens Healthineers Profile
7.7.2 Siemens Healthineers Main Business
7.7.3 Siemens Healthineers Interstitial Lung Disease (ILD) Products, Services and Solutions
7.7.4 Siemens Healthineers Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.7.5 Siemens Healthineers Recent Developments
8 Industry Chain Analysis
8.1 Interstitial Lung Disease (ILD) Industrial Chain
8.2 Interstitial Lung Disease (ILD) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Interstitial Lung Disease (ILD) Sales Model
8.5.2 Sales Channel
8.5.3 Interstitial Lung Disease (ILD) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer